IP Library Granted Patent US 8,460,635
Granted Patent B2
US 8,460,635 · App. 12/735,544 · Granted Jun 11, 2013

Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,460,635
App. No.
12/735,544
Granted
Jun 11, 2013
Kind
B2
Abstract

Synthetic peptidomimetic derivatives and phenyl group derivatives of Fenretinide (4-HPR) are disclosed, as are their uses as therapeutic, diagnostic and imaging agents for cancer and other diseases.

Claims (20)

1. A compound having the structure:

wherein R is OH;

wherein R 1 , R 2 and R 3 are independently H, Br, Cl, I, F, alkyl, aryl, OH, NO 2 , NHR 4 , OR 4 or heterocyclic, where R 4 is alkyl, aryl or heterocyclic;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein at least one of R 1 , R 2 and R 3 is OH, Br, Cl, I or F, and wherein at least one of R 1 , R 2 and R 3 is H.

3. The compound of claim 1 , wherein at least one of R 1 and R 3 is Br, Cl, I or F.

4. The compound of claim 1 , wherein R 2 is H or OH.

5. The compound of claim 1 , wherein R 3 is I.

6. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is radiolabeled.

10. The compound of claim 1 , wherein the compound further comprises a nanoparticle conjugated to position R, R 1 , R 2 or R 3 .

11. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier or diluent.

12. A method of treating a subject having cancer comprising administering the compound of claim 1 to the subject in an amount and manner effective to treat cancer in the subject.

13. The method of claim 12 , wherein the cancer is breast cancer, a rhabdoid tumor, a neuroblastoma, ovarian cancer, renal cancer, a malignant glioma or prostrate cancer.

14. A method of treating a subject having a disease comprising administering the compound of claim 1 to the subject in an amount and manner effective to treat the disease, wherein the disease is diabetes, AIDS, Alzheimer's Disease, cystic fibrosis, allergic encephalomyelitis or ichthyosis.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036888/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036875/0147 →